Gene Therapy Immunogenicity - Virtual Summit

Immunogenicity compromises both the efficacy and safety of gene therapies and thus represents one of the most prominent challenges that must be overcome in the field. Uniting translational, clinical, regulatory and manufacturing gene therapy functions, the inaugural Gene Therapy Immunogenicity Summit is the industry's definitive meeting enabling you to better measure, modulate and predict immune response and drive transformative treatments through the clinic to patients.

Conference Ticket (1st Release): USD 1399.0

Conference Ticket (2nd Release): USD 1599.0

Conference Ticket (3rd Release): USD 1799.0

Conference Ticket (Final Release): USD 1999.0

Brochure: https://go.evvnt.com/614539-3?pid=4832

Speakers:

Barry Byrne, Professor and Associate Chairman, University of Florida,

Mark Milton, Area Head of Ophthalmology, Novartis,

Sander van Deventer, Executive Vice President, uniQure and more.